In the second segment of this panel, the use of sacituzumab govitecan monotherapy and in combination with other treatments is discussed. Dr. Powles was joined by Andrea Apolo, MD, of the National Institute of Health; Petros Grivas, MD, PhD, of the University of Washington; Shilpa Gupta, MD, of Cleveland Clinic; and Kala Sridhar, MD, of Princess Margaret Cancer Center.
The Uromigos Live & Unplugged 2024
The Uromigos Live & Unplugged 2024 took place September 27-29 in Nashville, Tennessee.
The meeting was the third annual in-person event hosted by Thomas Powles, MD, and Brian Rini, MD, FASCO, in partnership with Mashup Media, featuring expert panels and audience discussion around the latest data in genitourinary oncology and vision for the future.
See below for coverage from the live event. Follow GU Oncology Now on X for the latest updates and check out videos from last year’s meeting.
Advertisement
In the second part of the session, the panel highlights some of the most important recent developments in papillary RCC.
In part one of the session, the panelists dive into an in-depth exploration and debate on the results of SUNNIFORECAST.
In the final part of this session, the panel discusses the nuances of re-challenging patients with PD-1 therapies.
The panel discusses the use of immunotherapy, specifically PD-1 based therapies, in renal cell carcinoma.
Part two features a discussion on the timing and rationale behind conducting trials for re-challenging patients.
The panelists discuss the use of immune checkpoint inhibitors and re-challenging patients with PD-1/PD-L1 therapies.
The panelists examine the existing data for T cell engagers in CRPC and how the data might affect clinical practice.
The panelists discuss T cell engagers, including an introduction and discussion of cytokine release syndrome.
The panel discusses the emerging field of PSMA-targeted alpha radioligand therapy, with a focus on HK2.
The panel discusses the results of PEACE-3, which evaluated enzalutamide with or without radium-223 for MCRPC.
The panel discusses two significant trials in metastatic hormone-sensitive prostate cancer.
Part 2 of the Radioligands session from Uromigos Live 2024 features a discussion on the SPLASH results from ESMO 2024.
The first part of five segments from the Uromigos Live 2024 session on radioligands.
During the final part of this panel, novel ADCs are explored and analyzed for use in different settings.
During the fourth segment of this panel, novel ADCs including HER3, Nectin-4, and BT8009 are analyzed.
In the third part of this panel, the use of HER2 ADCs in bladder cancer is explored.
In the second segment of this panel, the use of sacituzumab govitecan monotherapy and combinations is discussed.
In the first part of this panel, the use and impact of enfortumab vedotin in the bladder cancer landscape is considered.
The panelists wrap up this peri-operative therapy session with what the envision for the future for sparing bladders.
In this third segment, the panelists discuss bladder-sparing approaches.
The second part of this four-part segment includes conversation about ctDNA in bladder cancer.
The first part of four segments from the panel session on peri-operative therapy in bladder cancer.
Dr. Dorff shares highlights from Uromigos Live 2024 and talks about the role of ADT in prostate cancer treatment.
Listen to the podcast format of the kidney cancer panel on IO after IO therapy from Uromigos Live 2024.
Watch the "Front-Line Therapy in Papillary Renal Cancer" session from Uromigos Live 2024.
View the live recording of the "The Uromigos' Definition of Oligometastatic" session from Uromigos Live 2024.
Listen to the podcast format of the peri-operative therapy in bladder cancer panel from Uromigos Live 2024.
View the IO Rechallenge panel session from Uromigos Live & Unplugged 2024, recorded live in Nashville.
Listen to the podcast format of the kidney cancer panel on TKI vs Ipi/Nivo vs IO/TKI from Uromigos Live 2024.
Listen to the podcast format of the panel on radioligand data in prostate cancer from Uromigos Live 2024.
The Radioligands panel at Uromigos Live & Unplugged 2024 explored the role of RLT in prostate cancer treatment.
Listen to the podcast format of the panel on T cell directed therapy in prostate cancer from Uromigos Live 2024.
Watch the T Cell Directed Therapy in Prostate Cancer session from Uromigos Live 2024.
Listen to the podcast format of the panel on on emerging ADC data in bladder cancer from Uromigos Live 2024.
View the live recording of the "Will New Antibody Drug Conjugates Cure Bladder Cancer?" session from Uromigos Live 2024.
Peri-Operative Therapy in Urothelial Carcinoma: Live Session From The Uromigos Live & Unplugged 2024
Featuring Tom Powles, MD; Petros Grivas, MD; Shilpa Gupta, MD; Kala Sridhar, MD; and Andrea Apolo, MD. 
Dr. Rini talks about the exciting sessions and entertainment in store for guests at The Uromigos Live and Unplugged 2024.
Advertisement
Uromigos Cup 2024
Drs. Axel Bex, Christian Blank, Laura Mertens and Micheil Van der Heijden get a chance to win The Uromigos Cup.
Drs. Viktor Grünwald, Boris Hadaschik and Gunhild Von Amsberg answer trivia for the Uromigos Cup qualifying round.
Drs. Nobuaki Matsubara, Hiroshi Kitamura and Yuji Miura answer trivia questions set by Tom and Brian for the Uromigos Cup.
Drs. Danny Heng, Christian Kollmannsberger and Kala Sridhar attempt to take on Team LA to win the Uromigos Cup.
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.